Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"

被引：0
|
作者：
Jiang, Yanfang [1 ]
Zhang, Lei [2 ,3 ]
机构：
[1] First Hosp Jilin Univ, Genet Diag Ctr, Changchun, Peoples R China
[2] Med Res Ctr, Key Lab Digital Technol Med Diagnost Zhejiang Prov, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2024.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e43 / e43
页数：1
相关论文
共 50 条
  • [41] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [42] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [43] Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    van Geffen, Wouter H.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (09):
  • [44] Clinical Data for KRAS G12C Inhibitors
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
  • [45] Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors
    Hong, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 612 - 614
  • [46] Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
    Reale, M. L.
    Passiglia, F.
    Brambilla, M.
    Pasello, G.
    Minuti, G.
    Bulotta, A.
    Pizzutilo, P.
    Sini, C.
    Costa, J.
    Roca, E.
    Bria, E.
    Pilotto, S.
    Genova, C.
    Metro, G.
    Citarella, F.
    Bordi, P.
    Russo, A.
    Chiari, R.
    Andrikou, K.
    Novello, S.
    ANNALS OF ONCOLOGY, 2023, 34
  • [47] The sooner, the better: early clearance of plasma circulating tumor DNA in patients with advanced KRAS G12C mutant non-small cell lung cancer
    Garcia-Pardo, Miguel
    Garrido, Pilar
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 215 - 219
  • [48] Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor
    Cardona, Panli
    Dutta, Sandeep
    Houk, Brett
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (11): : 1219 - 1226
  • [49] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [50] Clinical validation of plasma cell-free DNA (cfDNA) sequencing in the phase 2 trial of sotorasib in patients (pts) with KRAS p.G12C mutated NSCLC.
    Bauml, Joshua M.
    Li, Bob T.
    Velcheti, Vamsidhar
    Govindan, Ramaswamy
    Fontecedro, Alessandra Curioni
    Dooms, Christophe
    Takahashi, Toshiaki
    Duda, Andrew W.
    Odegaard, Justin
    Cruz-Guilloty, Fernando
    Jin, Liming
    Zhang, Ying
    Skoulidis, Ferdinandos
    CANCER RESEARCH, 2021, 81 (13)
12345